releases blood sugar control injection in the US market Lupin Ltd launched Liraglutide injection for type 2 diabetes control in the US, available in an 18 mg/3 mL single-patient prefilled pen. The product, bioequivalent to Victoza, is used in adults and children aged 10 years and above with type 2 diabetes. Lupin also received USFDA approval for Rivaroxaban for Oral Suspension and a generic version of Biktarvy tablets, used in HIV treatment. Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations.